{"organizations": [], "uuid": "422a531acb432812e45349ab45b356a644d5fd17", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 16}, "facebook": {"likes": 61, "shares": 61, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s2.reutersmedia.net/resources/r/?m=02&d=20180122&t=2&i=1224016770&w=1200&r=LYNXMPEE0L03G", "site_section": "http://feeds.reuters.com/reuters/businessNews", "section_title": "Reuters: Business News", "url": "https://www.reuters.com/article/us-bioverativ-m-a-sanofi-fr/sanofi-near-deal-to-buy-bioverativ-for-more-than-11-5-billion-wsj-idUSKBN1FB05Y", "country": "US", "domain_rank": 408, "title": "Sanofi set to buy Bioverativ for more than $11.5 billion: WSJ", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T04:22:00.000+02:00", "replies_count": 0, "uuid": "422a531acb432812e45349ab45b356a644d5fd17"}, "author": "", "url": "https://www.reuters.com/article/us-bioverativ-m-a-sanofi-fr/sanofi-near-deal-to-buy-bioverativ-for-more-than-11-5-billion-wsj-idUSKBN1FB05Y", "ord_in_thread": 0, "title": "Sanofi set to buy Bioverativ for more than $11.5 billion: WSJ", "locations": [], "entities": {"persons": [{"name": "bioverativ", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "bioverativ", "sentiment": "none"}], "organizations": [{"name": "sanofi", "sentiment": "negative"}, {"name": "wsj", "sentiment": "negative"}, {"name": "alnylam pharmaceuticals", "sentiment": "none"}, {"name": "johnson & johnson", "sentiment": "none"}, {"name": "actelion", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "wsj reuters staff", "sentiment": "none"}, {"name": "bioverativ inc", "sentiment": "none"}, {"name": "sanofi sa", "sentiment": "none"}, {"name": "wall street journal", "sentiment": "none"}, {"name": "journal", "sentiment": "none"}, {"name": "biogen inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - Sanofi SA is close to a deal to take over U.S. drug maker Bioverativ Inc for more than $11.5 billion, the Wall Street Journal reported, citing people familiar with the matter.\nThe potential deal, which could be announced as soon as Monday, would value Bioverativ at about $105 a share, the Journal reported. ( on.wsj.com/2mYJulp )\nThe price represents a 64 percent premium to Bioverativ stockâ€™s close on Friday on the Nasdaq.\nBioverativ, a hemophilia drug maker, was separated from Biogen Inc early last year.\nSanofi has failed to land major deals after losing California-based cancer specialist Medivation to Pfizer Inc in 2016 and Swiss biotech company Actelion to Johnson & Johnson last year.\nEarlier this month, Sanofi said it obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with Alnylam Pharmaceuticals.\nSanofi and Bioverativ were not immediately available for comment outside regular business hours.\nReporting by Shubham Kalia in Bengaluru; Editing by Paul Simao and Gopakumar Warrier\n ", "external_links": [], "published": "2018-01-22T04:22:00.000+02:00", "crawled": "2018-01-22T04:31:00.000+02:00", "highlightTitle": ""}